10% Free customization
An acute ischemic stroke occurs when a blood clot obstructs a blood vessel supplying blood to the brain, leading to a sudden loss of neurological function. This blockage deprives brain tissue of essential oxygen and nutrients, causing cell death and potential long-term disability.This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
One of the significant drivers of the global acute ischemic stroke market is the rising incidence of lifestyle disorders. The rising ages and lifestyle-related diseases such as hypertension, diabetes, and obesity which leads to increases the risk of ischemic stroke. This results in increasing demand of drug or therapies during the treatment.
Despite the positive growth trajectory, several challenges continue to impact the global acute ischemic stroke market. One of the primary challenges is limited access to advanced care in low-resource settings. However, the advanced treatments like tPA and thrombectomy have improved outcomes, many regions lack the necessary infrastructure to deliver these therapies. This results in underdiagnosis and delayed treatments, significantly increasing stroke-related disability and mortality.
The global acute ischemic stroke market is also facing high cost of treatment. However, the cost of cutting-edge treatments like mechanical thrombectomy, tPA, and post-stroke rehabilitation can be prohibitive for patients and healthcare systems, particularly in developing regions.
The companies play pivotal roles in advancing the treatment landscape for ischemic stroke through the development of targeted therapies. Their ongoing research and collaborations are essential in improving patient outcomes and expanding therapeutic options in this market.
The competitive landscape of the global acute ischemic stroke market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market’s growth, especially as demand increases in emerging markets such as Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable therapies, the acute ischemic stroke market will continue to evolve, fostering new opportunities for both established and emerging companies.
Market Segmentation:
Segmentation 1: by Therapeutics
- Thrombolytic Therapies
- Antiplatelet Therapies
- Antihypertensive Therapies
- Anticoagulants
Segmentation 2: by Region
- North America
- Europe
- Asia-Pacific
This product will be delivered within 3-5 business days.
Table of Contents
Executive SummaryScope and DefinitionMarket/Product DefinitionKey Questions AnsweredAnalysis and Forecast Note5. Research Methodology
1. Global Acute Ischemic Stroke Market: Industry Outlook
2. Global Acute Ischemic Stroke Market, By Therapeutics, $Million, 2023-2035
3. Global Acute Ischemic Stroke Market, by Region, $Million, 2023-2035
4. Competitive Landscape and Company Profiles
List of Figures
List of Tables
Companies Mentioned
- Acticor Biotech
- Bristol-Myers Squibb
- Genentech, Inc
- Athersys|Healios K.K.
- Biogen Inc
- AbbVie
- Revalesio Corporation
- NoNO Inc.
- Bayer
- TrueBinding, Inc
- Lumosa Therapeutics
- Janssen Pharmaceutical
- Silver Creek Pharmaceuticals